ResearcherUniversity of MissouriActive in the last 2 years

Chiswili Yves Chabu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9585-5527; OpenAlex author ID A5051843581; NIH RePORTER profile ID 9716853. Sources: OpenAlex.

Their work

Papers: 4
Trials: 0
Grants: 1
Labs led: 0
Collaborators: 12

Papers, trials and grants by year

2022: 1 paper · 2023: none · 2024: 1 paper · 2025: none · 2026: 2 papers, 1 grant

Papers 4

Comparative Proteomic Profiling of Responses to Standard Systemic Treatment Regimens in Pancreatic Cancer. Co-author DOI 10.3390/cells15060531 ↗
CMTM6-Silencing Microbial Immunotherapy Reprograms PDAC Tumors and Restores T-cell Function Co-author DOI 10.64898/2026.01.26.701790 ↗
Pancreatic cancer tumor microenvironment is a major therapeutic barrier and target. Co-author DOI 10.3389/fimmu.2024.1287459 ↗
Single-cell RNA sequencing to characterize the response of pancreatic cancer to anti-PD-1 immunotherapy. Co-author DOI 10.1016/j.tranon.2021.101262 ↗

Grants 1

Tumor-Selective Bacterial Therapy to Reverse PDAC Immunosuppression R01CA314284 ↗

Closest collaborators

The 12 strongest of 12 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Paul de Figueiredo · 1 shared paper, 1 shared grant, 2026 · strength 1.49
- Grant Tumor-Selective Bacterial Therapy to Reverse PDAC Immunosuppression R01CA314284 ↗
- Paper CMTM6-Silencing Microbial Immunotherapy Reprograms PDAC Tumors and Restores T-cell Function DOI 10.64898/2026.01.26.701790 ↗
Bolni Marius Nagalo · 3 shared papers, 2024–2026 · strength 0.71
Omeed Moaven · 3 shared papers, 2024–2026 · strength 0.71
Conner Daniel Hartupee · 2 shared papers, 2024–2026 · strength 0.48
- Paper Pancreatic cancer tumor microenvironment is a major therapeutic barrier and target. DOI 10.3389/fimmu.2024.1287459 ↗
- Paper Comparative Proteomic Profiling of Responses to Standard Systemic Treatment Regimens in Pancreatic Cancer. DOI 10.3390/cells15060531 ↗
Mitesh J. Borad · 1 shared paper, 2026 · strength 0.24
- Paper Comparative Proteomic Profiling of Responses to Standard Systemic Treatment Regimens in Pancreatic Cancer. DOI 10.3390/cells15060531 ↗
Sudhakar Ammanamanchi · 1 shared paper, 2026 · strength 0.24
- Paper Comparative Proteomic Profiling of Responses to Standard Systemic Treatment Regimens in Pancreatic Cancer. DOI 10.3390/cells15060531 ↗
Amirsalar Mansouri · 1 shared paper, 2026 · strength 0.24
- Paper Comparative Proteomic Profiling of Responses to Standard Systemic Treatment Regimens in Pancreatic Cancer. DOI 10.3390/cells15060531 ↗
John H. Stewart · 1 shared paper, 2026 · strength 0.24
- Paper Comparative Proteomic Profiling of Responses to Standard Systemic Treatment Regimens in Pancreatic Cancer. DOI 10.3390/cells15060531 ↗
Jiří Adamec · 1 shared paper, 2026 · strength 0.24
- Paper Comparative Proteomic Profiling of Responses to Standard Systemic Treatment Regimens in Pancreatic Cancer. DOI 10.3390/cells15060531 ↗
Jing Zhou · 1 shared paper, 2022 · strength 0.15
- Paper Single-cell RNA sequencing to characterize the response of pancreatic cancer to anti-PD-1 immunotherapy. DOI 10.1016/j.tranon.2021.101262 ↗
Eric T. Kimchi · 1 shared paper, 2022 · strength 0.15
- Paper Single-cell RNA sequencing to characterize the response of pancreatic cancer to anti-PD-1 immunotherapy. DOI 10.1016/j.tranon.2021.101262 ↗
Guangfu Li · 1 shared paper, 2022 · strength 0.15
- Paper Single-cell RNA sequencing to characterize the response of pancreatic cancer to anti-PD-1 immunotherapy. DOI 10.1016/j.tranon.2021.101262 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.